Andrea Rueda Liñares

ORCID: 0000-0001-7611-9081
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Atrial Fibrillation Management and Outcomes
  • Infective Endocarditis Diagnosis and Management
  • Heart Failure Treatment and Management
  • Cardiovascular Function and Risk Factors
  • Hepatitis B Virus Studies
  • Cardiac Valve Diseases and Treatments
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Diabetes Treatment and Management
  • Blood disorders and treatments
  • Cardiac pacing and defibrillation studies
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Cardiovascular Effects of Exercise
  • Cardiac Structural Anomalies and Repair
  • Venous Thromboembolism Diagnosis and Management
  • Peptidase Inhibition and Analysis
  • Dermatological and Skeletal Disorders
  • Mechanical Circulatory Support Devices
  • Vascular Procedures and Complications
  • Diverticular Disease and Complications
  • Erythropoietin and Anemia Treatment
  • Hematopoietic Stem Cell Transplantation
  • Vascular Anomalies and Treatments
  • Tracheal and airway disorders
  • Congenital Anomalies and Fetal Surgery

Hospital Central de la Defensa Gómez Ulla
2017-2024

Hospital Universitario Fundación Jiménez Díaz
2023

Hospital Clínico San Carlos
2017-2018

Ministry of Defense
2018

Universidad Nacional de Colombia
2017

Infant
2017

Central University Hospital of Asturias
2004-2009

Clínica Santa María
2008

Sodium-glucose cotransporter inhibitors (SGLT2i) have demonstrated a reduction in cardiovascular events diabetes and heart failure (HF). The mechanisms underlying this benefit are not well known data contradictory. purpose of study is to analyse the effect dapagliflozin on cardiac structure function patients with normal ejection fraction. Between October 2020 2021, we consecutively included 31 diabetic without prior history SGLT2i use. In all them, treatment was started. At inclusion during...

10.3390/jcm12206698 article EN Journal of Clinical Medicine 2023-10-23

Antithrombotic management in patients with atrial fibrillation (AF) that have undergone heart valve surgery may be challenging, especially the context of thromboembolic events during follow-up. The combination pharmacological therapies modern transcatheter interventions allows these more complex cases to overcome.

10.1093/ehjcr/ytab263 article EN cc-by-nc European Heart Journal - Case Reports 2021-07-01

Catheter ablation(CA) is an increasingly used therapeutic tool for the treatment of atrial fibrillation (AF). Atrioesophageal fistula (AEF) one most dreaded complications CA and its incidence ranges from <0.1% to 0.25% .Despite rarity, AEF accounts a high proportion among fatal AF ablation. We present rare case after cryo-ablation presenting as infective endocarditis. A 73-year-old male with history pulmonary vein isolation using radiofrequency ablation 4 weeks prior admission, presented...

10.22541/au.170664640.06262806/v1 preprint EN Authorea (Authorea) 2024-01-30

Abstract In this rare case of intrahepatic cholangiocarcinoma (ICC) tumor thrombus with right atrial (RA) invasion, we describe its diagnostic workup based on cardiac magnetic resonance imaging (cMRI). An 85‐year‐old man underwent transthoracic echocardiography due to dyspnea, revealing a RA mass. Comprehensive cMRI evaluation, including cine bright blood, T1‐ and T2‐weighed, fat‐suppressed, contrast‐enhanced imaging, was performed diagnosis ICC invasion made. This first description...

10.1111/echo.15079 article EN Echocardiography 2021-05-19

Abstract BACKGROUND Sodium-glucose cotransporter inhibitors (SGLT2i) have proven a reduction in cardiovascular events diabetic patients with and without heart failure (HF), as well non-diabetic HF. The mechanisms underlying this benefit are not known, contradicting data on the changes that SGLT2i produce cardiac function structure. METHODS Between October 2020 2021, 31 prior history of use normal ejection fraction (> 50%), glycated hemoglobin < 6.5%, renal clearance rate > 60...

10.21203/rs.3.rs-3280284/v1 preprint EN cc-by Research Square (Research Square) 2023-08-25

Abstract Introduction Sodium-glucose cotransporter inhibitors (SGLT2i) have proven a reduction in cardiovascular events diabetic patients with and without heart failure (HF), as well non-diabetic reduced preserved ejection fraction (EF). The mechanisms underlying this benefit are not known, contradicting data on the changes that SGLT2i produce cardiac function structure. Methods Between October 2020 2021, 31 prior history of use normal EF (>50%), glycated hemoglobin <6.5%,...

10.1093/eurheartj/ehad655.080 article EN cc-by European Heart Journal 2023-11-01

We performed a retrospective analysis, of allogenic stem cell transplantation (allo-SCT) results, in 40 patients with diagnosis acquired aplastic anemia or Fanconni Anemia, transplant center Bogotá, Colombia, between 1996 and 2007. During that period, 42 transplants were patients. 28 (70%) 12 (30%) Fanconni's Anemia. 17 (42.5%) female/25 (62.5%) male. Mean age was 22 years (4–57). Stem cells obtained from peripheral blood 36 (90%) bone marrow 6 (15%). The majority high risk; the mean time to...

10.1016/j.bbmt.2007.12.321 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2008-01-28

Results: 82 (75% men; mean age 54±16 years) patients were analyzed.At least 1 suitable vector was identified in 74 (90%) with MST and 76 (93%) AST (p=0.576).At two vectors appropriate 53 (65%) 60 (73%) (p=0.238).No detected 8 6 AST.Overall, out of 492 ECG analyzed, 38 passed the test but didn't pass MST.Agreement between tools moderate (Kappa=0.549;standard error=0.040;CI=0.470-0.627). Conclusion:The novel previous are associated comparable passing rate, although agreement seems only...

10.1093/eurheartj/ehx493.p6392 article EN European Heart Journal 2017-08-01

Introducción. La enfermedad de Von Willebrand es el trastorno la coagulación más frecuente, las manifestaciones clínicas son variables, mayoría veces leves-moderadas. Objetivo. Describir características y laboratorio

10.51643/22562915.248 article ES cc-by-nc-sa Revista Colombiana de Hematología y Oncología 2017-12-01

El carcinoma hepatocelular (CHC) es la principal neoplasia maligna del hígado.Aumentó su incidencia en los últimos años, hasta el punto de ser actualmente quinto tumor más frecuente mundo, salvo excepciones países Sudeste Asiático y Africa, donde puede aparecer portadores virus hepatitis B sin hepatopatía avanzada.Ocurre pacientes con cirrosis hepática, que constituye causa muerte 1, 2 .La ajustada para edad sur Europa se sitúa 10 casos por 100.000 habitantes varones.No todos tienen mismo...

10.4321/s0378-48352004000400019 article ES Oncología (Barcelona) 2004-04-01
Coming Soon ...